With 250 rare diseases newly identified every year, scientists can barely keep up — even as the healthcare system fails millions of Americans whose rare diseases have already been diagnosed. That’s the warning from Christopher P. Austin, MD, director of the National Center for Advancing Translational Studies(NCATS) at the…
News
“Excited and beyond belief” is how Ron Bartek, co-founder and president of the Friedreich’s Ataxia Research Alliance (FARA), describes current prospects for finding treatments for the incurable genetic disease that claimed his son, Keith, at age 24. Bartek spoke to Friedreich’s Ataxia News on the sidelines of the recent…
With an estimated 1.37 billion inhabitants, India will likely surpass China in five years as the world’s most populous country. That also means it will have more rare-disease patients than any nation. It already has more than twice as many as the 28-member European Union. Harsha K. Rajasimha, a genomics…
The oral glucose tolerance test showed higher sensitivity, compared with other diagnostic tools, and was able to detect up to three times more metabolic abnormalities in Friedreich ataxia patients, who commonly experience diabetes and impaired sugar tolerance, according to a small study. “Clinicians in charge of Friedreich ataxia patients and researchers…
Despite some benefits seen in clinical measures like cardiac health and reports by Friedreich’s ataxia (FA) patients of lesser fatigue and better function upon treatment with idebenone in clinical trials, a new two-month study found little difference between those given the therapy and those on placebo. The study, “…
Takeda and StrideBio have established a collaboration to develop new, more effective adeno-associated viruses (AAV) to be used as vehicles for in vivo delivery of gene therapies for Friedreich’s ataxia (FA) and other diseases. “StrideBio’s expertise and unique gene therapy technology holds great potential for significantly advancing…
Adding a molecule that specifically binds iron in mitochondria to sun creams could help protect the skin cells of Friedreich’s ataxia (FA) patients from their increased sensitivity to damage caused by ultraviolet A (UVA) radiation. Besides FA patients, this discovery might benefit people living with other disorders also characterized…
A new data-sharing platform recently launched by the Critical Path Institute’s (C-Path) Data Collaboration Center (DCC) and the Friedreich’s Ataxia Research Alliance (FARA) is designed to ultimately lead to the development of effective treatments for Friedriech’s ataxia (FA). Called the Friedreich’s Ataxia Integrated Clinical…
Madeline Collin, a 24-year-old activist with Gaucher disease, worries that patients like her will suffer deeply if Britain leaves the European Union (EU), as scheduled, at the end of this month. Collin is an expert on the subject. For her University of Bathdissertation, she analyzed Brexit’s long-term impact…
Minoryx Therapeutics announced it will soon launch a Phase 2 trial in Spain to evaluate its lead therapeutic candidate, MIN-102, in patients with Friedreich’s ataxia. The study (2018-004405-64), named FRAMES, was approved by the Spanish Agency of Medicines and Medical Devices (AEMPS) and is expected to initiate patient…
Recent Posts
- The importance of leaning toward hope in life with Friedreich’s ataxia
- New study finds low vitamin D levels common among FA patients in UK
- Finding meaning in the randomness of having Friedreich’s ataxia
- 17-year-old advocate shares her NMOSD story to raise awareness
- The forced adversity of Friedreich’s ataxia can lead to personal growth